648 related articles for article (PubMed ID: 28751098)
41. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States.
Poorvu PD; Vaz-Luis I; Freedman RA; Lin NU; Barry WT; Winer EP; Hassett MJ
Breast Cancer Res Treat; 2018 Apr; 168(3):727-737. PubMed ID: 29332137
[TBL] [Abstract][Full Text] [Related]
42. Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.
Gauthier G; Gagnon-Sanschagrin P; Guérin A; Burne R; Small T; Niravath P; Dalal AA
Adv Ther; 2018 Apr; 35(4):503-514. PubMed ID: 29556908
[TBL] [Abstract][Full Text] [Related]
43. Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status.
Gonçalves A; Deblock M; Esterni B; Tarpin C; Bertucci F; Gilabert M; Charafe-Jauffret E; Jacquemier J; Houvenaeghel G; Extra JM; Viens P
Anticancer Drugs; 2009 Nov; 20(10):946-52. PubMed ID: 19741502
[TBL] [Abstract][Full Text] [Related]
44. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
45. Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.
Li N; Hao Y; Xie J; Lin PL; Zhou Z; Zhong Y; Signorovitch JE; Wu EQ
Curr Med Res Opin; 2015 Aug; 31(8):1573-82. PubMed ID: 26074049
[TBL] [Abstract][Full Text] [Related]
46. Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer.
Dalal AA; Gauthier G; Gagnon-Sanschagrin P; Burne R; Guérin A; Niravath P; Small T
Adv Ther; 2018 Sep; 35(9):1356-1367. PubMed ID: 30105655
[TBL] [Abstract][Full Text] [Related]
47. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application.
Richardson D; Zhan L; Mahtani R; McRoy L; Mitra D; Reynolds M; Odom D; Hollis K; Kaye JA; Jones C; Hargis J
Breast Cancer Res Treat; 2021 May; 187(1):113-124. PubMed ID: 33428072
[TBL] [Abstract][Full Text] [Related]
48. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
49. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
[TBL] [Abstract][Full Text] [Related]
50. Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study.
Geisler J; Karihtala P; Tuxen M; Valachis A; ; Holm B
Acta Oncol; 2023 Dec; 62(12):1680-1688. PubMed ID: 37713138
[TBL] [Abstract][Full Text] [Related]
51. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Manso L; Palomo AG; Pérez Carrión R; Cassinello J; Gallegos Sancho I; Chacón López-Muñiz I; Olier C; Fernández-Aramburo A; Llorca C; González X; Llorente R; Torregrosa D; Álvarez I; Gálve E; Bueno C; Garau I; García MJ; González-Santiago S; Ballesteros AI; Blanco E; Galán A; González S; Perelló A; Cortés-Funes H; Grávalos C
Anticancer Res; 2015 Dec; 35(12):6941-50. PubMed ID: 26637920
[TBL] [Abstract][Full Text] [Related]
52. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Hartkopf AD; Huober J; Volz B; Nabieva N; Taran FA; Schwitulla J; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lux MP; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Fersis N; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A
Breast; 2018 Feb; 37():42-51. PubMed ID: 29100043
[TBL] [Abstract][Full Text] [Related]
53. Chemosensitization role of fulvestrant in combination with chemotherapy in postmenopausal hormone receptor positive and human epidermal growth factor negative metastatic breast cancer.
Luo QQ; Adhikari VP; Zhao CX; Wu H; Dai W; Li X; Wu YT; Wu KN; Kong LQ
Med Hypotheses; 2016 Dec; 97():59-63. PubMed ID: 27876131
[TBL] [Abstract][Full Text] [Related]
54. First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.
Tang DH; Li N; Du EX; Peeples M; Chu L; Xie J; Barghout V
Curr Med Res Opin; 2017 Dec; 33(12):2137-2143. PubMed ID: 28994315
[TBL] [Abstract][Full Text] [Related]
55. Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland.
Teerenhovi H; Tuominen S; Nurmi-Rantala S; Hemmilä P; Ellonen A
Oncologist; 2021 Aug; 26(8):e1372-e1380. PubMed ID: 33955109
[TBL] [Abstract][Full Text] [Related]
56. Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.
O'Shaughnessy J; Thaddeus Beck J; Royce M
Cancer Treat Rev; 2018 Sep; 69():204-214. PubMed ID: 30092555
[TBL] [Abstract][Full Text] [Related]
57. Antrodia cinnamomea is a potentially effective complementary medicine for adjuvant therapy against breast cancer with bone metastasis: A case report.
Long H; Hu CT; Prijatelj V; Weng CF
Medicine (Baltimore); 2020 Jul; 99(27):e20808. PubMed ID: 32629666
[TBL] [Abstract][Full Text] [Related]
58. Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer - Results from the prospective German TMK cohort study.
Fietz T; Tesch H; Rauh J; Boller E; Kruggel L; Jänicke M; Marschner N;
Breast; 2017 Aug; 34():122-130. PubMed ID: 28586735
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Schramm A; Friedl TW; Schochter F; Scholz C; de Gregorio N; Huober J; Rack B; Trapp E; Alunni-Fabbroni M; Müller V; Schneeweiss A; Pantel K; Meier-Stiegen F; Hartkopf A; Taran FA; Wallwiener D; Janni W; Fehm T
Arch Gynecol Obstet; 2016 Feb; 293(2):271-81. PubMed ID: 26354331
[TBL] [Abstract][Full Text] [Related]
60. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.
Blackwell KL; Burstein HJ; Storniolo AM; Rugo HS; Sledge G; Aktan G; Ellis C; Florance A; Vukelja S; Bischoff J; Baselga J; O'Shaughnessy J
J Clin Oncol; 2012 Jul; 30(21):2585-92. PubMed ID: 22689807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
